Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16603564 | 0.91 | KDM4E (0.33) | KDM4ESMN1; SMN2ALPGMCL1ALDH1A1 | |
| SCHEMBL15616957 | 0.88 | KDM4E (0.43) | KDM4EATML3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL15616915 | 0.84 | KDM4E (0.37) | KDM4EATML3MBTL1SMN1; SMN2ALPG | |
| SCHEMBL15616961 | 0.84 | KDM4E (0.37) | KDM4EATML3MBTL1SMN1; SMN2ALPG | |
| SCHEMBL10014422 | 0.83 | KDM4E (0.48) | KDM4EATML3MBTL1SMN1; SMN2ALPG | |
| SCHEMBL15616960 | 0.82 | KDM4E (0.38) | KDM4EATML3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL26517159 | 0.81 | PKM (0.39) | KDM4EATML3MBTL1SMN1; SMN2ALPG | |
| SCHEMBL27239732 | 0.80 | — | — | |
| SCHEMBL15616947 | 0.79 | KDM4E (0.34) | KDM4EATML3MBTL1SMN1; SMN2ALPG | |
| SCHEMBL38654967 | 0.79 | CYP2A6 (0.36) | KDM4EATML3MBTL1SMN1; SMN2ALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240196741-A1 | ORGANIC COMPOUND, OPTO-ELECTRONIC DEVICE INCLUDING THE SAME, ELECTRONIC APPARATUS INCLUDING THE OPTO-ELECTRONIC DEVICE, AND ELECTRONIC DEVICE INCLUDING THE ELECTRONIC APPARATUS | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-06-13 | — | — | US | disclosed |
| CN-117939985-A | Organic compound, electro-optical device, electronic apparatus, and electronic apparatus | 三星显示有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20150349271-A1 | Novel Compound, Light-Emitting Element Comprising same and Electronic Device Comprising the Light-Emitting Element | LMS CO., LTD. (KR) | 2015-12-03 | — | — | US | disclosed |
| US-20150349271-A1 | Novel Compound, Light-Emitting Element Comprising same and Electronic Device Comprising the Light-Emitting Element | LMS CO., LTD. (KR) | 2015-12-03 | — | — | US | disclosed |
| WO-2014025231-A2 | NOVEL COMPOUND, LIGHT-EMITTING ELEMENT COMPRISING SAME AND ELECTRONIC DEVICE COMPRISING THE LIGHT-EMITTING ELEMENT | 주식회사 엘엠에스 (KR) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150349271-A1 | Novel Compound, Light-Emitting Element Comprising same and Electronic Device Comprising the Light-Emitting Element | SUN2, NFE2L2, NR2E3 | KDM4E 2182/4885ATM 4028/4885L3MBTL1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.